【新股消息 | 百力司康递表港交所 公司核心产品为BB-1701 BB-1705等三款ADC处于临床阶段】智通财经APP

智通财经
29 Jun
【新股消息 | 百力司康递表港交所 公司核心产品为BB-1701 BB-1705等三款ADC处于临床阶段】智通财经APP获悉,据港交所6月29日披露,BlissBio Inc.(简称:百力司康)向港交所主板递交上市申请,高盛、华泰国际及建银国际为联席保荐人。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10